Find a Clinical Trial
-
REACH Clinical Trial
Diagnosis Requirements: Mild cognitive impairment or Alzheimer’s
Age Eligibility: Ages 55 to 89 years
Medication: Rapamycin or placeboThe REACH clinical trial is 1 of 16 trials worldwide offering promising therapies for Alzheimer’s disease and dementia funded by the Alzheimer’s Association’s Part the Cloud global research grant program and Bill Gates. The trial will evaluate the use of Rapamycin to slow progression of amnestic mild cognitive impairment and early-stage Alzheimer’s. It will also collect vital information on Alzheimer’s markers and relevant outcomes for future clinical trials.
-
AHEAD 3-45 Study
Diagnosis Requirements: None
Age Eligibility: 55 to 80 years
Medication: Lecanemab or placeboThis study reviews a new treatment to prevent memory decline and slow the earliest symptoms of Alzheimer’s disease.
-
Heart Function and Brain Health Study
Diagnosis Requirements: Normal Heart Function or Diastolic Dysfunction
Age Eligibility: 60 years or older
The purpose of this clinical trial is to study heart function in relation to brain health.
-
7T MRI Study of How COVID-19 Affects the Brain
Diagnosis Requirements: None
Age Eligibility: 45 to 80 years
Medication: NoneStudying COVID-19’s long-term neurological and psychological impacts.
-
DiverseVCID: Diverse Vascular Contributions to Cognitive Impairment and Dementia
Diagnosis Requirements: None
Age Eligibility: 65 to 90 years
Medication: NoneThe results of this study will be used to develop and validate a predictive risk model to inform future care.
-
MarkVCID: Biomarkers for Vascular Contribution to Cognitive Impairment and Dementia
Diagnosis Requirements: None or diagnosis of MCI or mild dementia
Age Eligibility: 60-90 years old
Medication: NoneDuring four annual assessments, we will compare your blood biomarkers and brain health to verify biomarkers as an accessible and affordable way to learn healthy aging from signs of dementia.